Physician profile
Christopher W Robb
NPI 1114074093
$23,374.63
in general payments reported to CMS, 2019-2025
38 companies · $5,209 in 2025
The $5,209 reported for 2025 was more than what 84% of Pediatric Dermatology providers received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,893 · 2020: $932 · 2021: $857 · 2022: $1,791 · 2023: $11K · 2024: $1,465 · 2025: $5,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $4,132 · Travel and Lodging: $1,976 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,697.50 |
| Food and Beverage | $4,132.42 |
| Travel and Lodging | $1,976.49 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $10,729.98 | 2021-2023 | Puraply Antimicrobial, Apligraf, Nushield |
| Galderma Laboratories, L.P. | $4,388.22 | 2019-2025 | Nemluvio, Aklief |
| Aclaris Therapeutics, INC. | $1,398.91 | 2019 | |
| Abbvie INC. | $1,195.21 | 2020-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $625.46 | 2020-2025 | Odomzo, Blu-U, Ilumya |
| Novartis Pharmaceuticals Corporation | $583.93 | 2019-2025 | |
| Janssen Biotech, INC. | $540.52 | 2019-2025 | Tremfya |
| Genentech USA, INC. | $360.77 | 2019-2025 | Erivedge, Xolair |
| Convatec INC. | $337.07 | 2025 | |
| Allergan, INC. | $320.63 | 2019-2022 | |
| Genzyme Corporation | $307.71 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $305.98 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $259.65 | 2020-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $210.79 | 2019-2024 | Olumiant, Taltz, Zepbound |
| Ucb, INC. | $197.91 | 2019-2025 | Bimzelx |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $188.78 | 2020-2025 | Otezla, Otezla |
| Incyte Corporation | $166.12 | 2022-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $149.76 | 2019-2023 | Arazlo, Jublia |
| Bard Peripheral Vascular, INC. | $143.08 | 2021 | |
| Strata Skin Sciences, INC. | $141.28 | 2020-2024 | Xtrac |
| Pfizer INC. | $125.01 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $99.85 | 2023-2025 | Sotyktu |
| Botanix Sb INC | $79.18 | 2025 | Sofdra |
| Biofrontera INC. | $71.24 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Octapharma USA, INC. | $69.91 | 2021 | |
| Glaxosmithkline, LLC. | $64.46 | 2020-2021 | |
| Almirall LLC | $56.13 | 2021-2025 | Seysara |
| Mayne Pharma Commercial LLC | $48.58 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $40.76 | 2025 | Zoryve |
| Journey Medical Corporation | $33.55 | 2022-2023 | |
| Inspire Medical Systems, INC. | $21.08 | 2024 | Inspire |
| Jubilant Hollisterstier LLC | $20.94 | 2019 | |
| Sensus Healthcare, INC. | $20.77 | 2024 | |
| Celgene Corporation | $18.70 | 2019 | |
| Dermira, INC. | $17.31 | 2020 | |
| Kaleo, INC. | $14.19 | 2019 | |
| Dusa Pharmaceuticals, INC. | $12.41 | 2019 | |
| Kerecis Limited | $8.80 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Robb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.